Table 1.
Baseline Differences between Those with Mild to Moderate AD with Slow Gait Speed at Baseline and Those Without (Univariate Analysis). ADAS-Cog = Alzheimer Disease Assessment Scale – Cognitive Subsection; CDR-Sb: Clinical Dementia Rating, Sum of Boxes, BMI: Body Mass Index
| Characteristic | No Slow Gait Speed (N = 332) |
Slow Gait Speed (N = 37) |
P-Value |
|---|---|---|---|
| Age, mean (SD) | 72.25 (8.02) | 77.68 (6.75) | < 0.001* |
| Gender, female (%) | 207 (62.35%) | 26 (70.27%) | 0.343 |
| BMI, mean (SD) | 25.44 (4.23) | 27.97 (5.56) | 0.005* |
| Group, nilvadipine (%) | 169 (50.9%) | 18 (48.65%) | 0.795 |
| Diagnosis Duration, median (IQR) | 0.90 (0.43–2.22) | 1.01 (0.48–1.71) | 0.687 |
| Symptom Duration, median (IQR) | 3.69 (2.20–5.25) | 3.45 (2.50–4.28) | 0.689 |
| Education, median (IQR) | 16 (14–18) | 14 (12–16) | 0.003* |
| Total Medications, median (IQR) | 5 (3–6.5) | 5 (4–8) | 0.022* |
| Antidepressant Use, N (%) | 126 (37.95%) | 18 (48.65%) | 0.206 |
| Benzodiazepine Use, N (%) | 40 (12.05%) | 3 (8.11%) | 0.479 |
| Total Comorbidities, median (IQR) | 4 (2–5) | 4 (3–6) | 0.009* |
| Diabetes, N (%) | 22 (6.63%) | 5 (13.51%) | 0.297 |
| Hypertension, N (%) | 94 (28.40%) | 14 (37.84%) | 0.232 |
| Arthritis, N (%) | 26 (7.83%) | 4 (10.81) | 0.529 |
| Baseline ADAS-Cog, mean (SD) | 32.49 (9.49) | 37.29 (11.56) | 0.002* |
| Baseline CDR-Sb, mean (SD) | 4.67 (2.44) | 6.13 (2.84) | 0.004* |